Literature DB >> 6744252

Mechanism of action of didemnin B, a depsipeptide from the sea.

L H Li, L G Timmins, T L Wallace, W C Krueger, M D Prairie, W B Im.   

Abstract

With the brush border membrane vesicles prepared from the rat kidney cortex, didemnin B and its parent compound, didemnin A function neither as a K+-specific ionophore nor as an ionophore for Na+ ions while other depsipeptide antibiotics such as valinomycin and gramicidin promote transmembrane movement of K+ and Na+ ions, respectively. Didemnin B inhibits protein synthesis and DNA synthesis much more than RNA synthesis and is in general more potent than didemnin A. Time course studies reveal that the action of didemnin B is rapid and cannot be reversed after 2 h in contact with the cells. The inhibition of protein synthesis is almost superimposable to that of L1210 cells growth. DNA synthesis is also markedly inhibited. These results collectively suggest that didemnin B acts differently, at least in part, from other depsipeptide antibiotics and its biological effect is primarily mediated through its inhibition of protein synthesis and to a lesser extent its inhibition of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744252     DOI: 10.1016/0304-3835(84)90095-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.

Authors:  J A Benvenuto; R A Newman; G S Bignami; T J Raybould; M N Raber; L Esparza; R S Walters
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

Review 2.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

3.  Phase I clinical study of didemnin B. A National Cancer Institute of Canada Clinical Trials Group study.

Authors:  J A Maroun; D Stewart; S Verma; E Eisenhauer
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

4.  Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.

Authors:  D M Shin; P Y Holoye; W K Murphy; A Forman; S C Papasozomenos; W K Hong; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.

Authors:  H G Chun; B Davies; D Hoth; M Suffness; J Plowman; K Flora; C Grieshaber; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 6.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

7.  Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cycloxazoline.

Authors:  D J Watters; H J Beamish; K A Marshall; R A Gardiner; G J Seymour; M F Lavin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Authors:  D M Shin; P Y Holoye; A Forman; R Winn; R Perez-Soler; S Dakhil; J Rosenthal; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis.

Authors:  C M Crews; W S Lane; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide.

Authors:  M B Hossain; D van der Helm; J Antel; G M Sheldrick; S K Sanduja; A J Weinheimer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.